CartiHeal’s cartilage regeneration implant raises $18.3 million
Israel based CartiHeal announced today an $18.3M financing round to finance the company’s recently-approved IDE clinical trial toward a PMA application. CartiHeal’s flagship Agili-C implant has been shown to promote regeneration of true hyaline cartilage and its subchondral bone simultaneously, without the use of cells, growth factors, or other exogenous agents. They are looking to demonstrate the Agili-C™ implant’s superiority over the surgical standard of care.
The investment was led by aMoon, together with CartiHeal’s existing investors: Johnson & Johnson Innovation, Peregrine Ventures and Elron, who has been consistently supporting and investing in CartiHeal over the years.
To read the full press release, click here.